pioglitazone has been researched along with Fatty Liver, Nonalcoholic in 162 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to evaluate the effectiveness of metformin and pioglitazone in combination with vitamin E on sonography grade and liver enzymes level in patients with non-alcoholic fatty liver disease." | 9.69 | Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial. ( Beheshtirouy, S; Gharekhani, A; Khoshbaten, M; Rezaee, H; Shayanrad, S, 2023) |
| "Pioglitazone is considered a potential therapy for non-alcoholic fatty liver disease (NAFLD)." | 9.41 | Response to pioglitazone in non-alcoholic fatty liver disease patients with ( Chen, H; Du, H; Jiang, Y; Li, M; Long, G; Ma, C; Ren, Y; Tian, J; Wang, Z; Xu, M; Xue, C; Zhao, Y, 2023) |
| " Dapagliflozin has shown non-inferiority compared with pioglitazone for glycemic control, and superiority regarding weight reduction in patients with type 2 diabetes." | 9.41 | Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. ( Aoki, S; Atsumi, T; Cho, KY; Kameda, H; Kurihara, Y; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Takase, T; Taneda, S; Yamamoto, K, 2021) |
| "Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease, NCT00633282 ." | 9.41 | Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. ( Chang, X; Gao, J; Ma, S; Wang, L; Wu, W; Xia, M; Yan, H, 2021) |
| " pioglitazone on hepatic fat content and serum fetuin A levels in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease." | 9.34 | Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. ( Qu, XN; Sun, ZY; Zhang, LY; Zhang, Y, 2020) |
| "The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone." | 9.22 | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. ( Bril, F; Cusi, K; Darland, C; Hardies, J; Hecht, J; Lomonaco, R; Musi, N; Orsak, B; Ortiz-Lopez, C; Portillo-Sanchez, P; Tio, F; Webb, A, 2016) |
| " Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3." | 9.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
| "To systematically evaluate the effects of pioglitazone in the treatment of patients with prediabetes or T2DM combined with NAFLD." | 9.12 | Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. ( Fu, J; Lian, J, 2021) |
| "We performed a meta-analysis of epidemiological studies evaluating exposure to pioglitazone and the risk for bladder cancer and compared these results to the drug's effects on cardiovascular disease (CVD) and non-alcoholic steatohepatitis (NASH)." | 8.98 | An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. ( Davidson, MB; Pan, D, 2018) |
| "The aim: To study the association between the effectiveness of treatment with pioglitazone non-alcoholic fatty liver disease (NAFLD) in patients with obesity and PPARG rs1801282 (Pro12Ala)-polymorphism in Ukrainians." | 8.02 | ASSOCIATION ANALYSIS OF PIOGLITAZONE EFFECTIVENESS IN TREATMENT OF NAFLD PATIENTS WITH OBESITY AND PPARG RS1801282 (PRO12ALA) GENOTYPE. ( Koliada, AK; Martynchuk, OA; Melnyk, NH; Rudenko, NN; Shypulin, VP; Tishchenko, VV, 2021) |
| " Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs)." | 7.91 | Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. ( Chaiyakunapruk, N; Chongmelaxme, B; Dilokthornsakul, P; Phisalprapa, P; Sawangjit, R, 2019) |
| "The study showed pioglitazone might exert an inhibitory effect on hepatic inflammation and fibrosis in NAFLD." | 7.85 | Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. ( Deng, W; Meng, Z; Sun, A; Yang, Z, 2017) |
| "To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone." | 7.83 | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016) |
| "This quasi experimental study was carried out to compare the efficacy of Pentoxifylline versus Pioglitazone in non-alcoholic fatty liver disease (NAFLD) among newly detected glucose intolerant patients attended at GHPD, BIRDEM, Dhaka, Bangladesh from March 2011 to May 2012." | 7.83 | Comparative Study between Pentoxifylline and Pioglitazone in the Treatment of Non-Alcoholic Fatty Liver Disease among Newly Detected Glucose Intolerant Patients. ( Ahmed, H; Alam, MS; Chowdhury, M; Karim, MR; Paul, RK; Saha, A, 2016) |
| " Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients." | 7.78 | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ( Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H, 2012) |
| "Combined treatment with pioglitazone-metformin can effectively reduce liver fat content and gamma-GT level in newly diagnosed diabetic patients with nonalcoholic fatty liver disease, and adverse events do not increase compared with the control group, showing good safety and tolerance." | 7.30 | Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study. ( Jianfang, F; Jianrong, L; Jie, M; Jing, X; Jingxuan, L; Kaiyan, M; Mengying, L; Qian, X; Qingzhen, H; Qiuhe, J; Taixiong, C; Wanxia, X; Wenjuan, Y; Xiling, G, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is a complex metabolic disorder that increases the risk for cardiovascular disease in patients with type 2 diabetes mellitus (T2DM)." | 7.30 | Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial. ( Ajdarkosh, H; Attaran, F; Emami, S; Ismail-Beigi, F; Khamseh, ME; Khoonsari, M; Malek, M; Sohrabi, M, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is known to be a health-related problem; there is no proven treatment for NAFLD." | 6.84 | Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. ( Akbarieh, S; Gohari, S; Heydari, AH; Jafari, S; Jameshoorani, M; Sajedi, B; Yaghoubi, M, 2017) |
| " The suggestion of this Expert Panel is that, pending forthcoming randomized clinical trials, physicians should consider using a PPARgamma agonist, such as pioglitazone, or, statin use in those with NAFLD/NASH at high CVD or HCC risk, alone and/or preferably in combination with each other or with ezetimibe, for the primary or secondary prevention of CVD, and the avoidance of cirrhosis, liver transplantation or HCC, bearing in mind that CVD is the main cause of death in NAFLD/NASH patients." | 6.55 | The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. ( Alexandrides, TK; Athyros, VG; Bilianou, H; Cholongitas, E; Doumas, M; Elisaf, MS; Ganotakis, ES; Germanidis, G; Giouleme, O; Goudevenos, J; Karagiannis, A; Karvounis, C; Katsiki, N; Kotsis, V; Kountouras, J; Liberopoulos, E; Mantzoros, C; Mikhailidis, DP; Pitsavos, C; Polyzos, S; Rallidis, LS; Richter, D; Tsapas, AG; Tselepis, AD; Tsioufis, K; Tziomalos, K; Tzotzas, T; Vasiliadis, TG; Vlachopoulos, C, 2017) |
| "This study aimed to evaluate the effectiveness of metformin and pioglitazone in combination with vitamin E on sonography grade and liver enzymes level in patients with non-alcoholic fatty liver disease." | 5.69 | Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial. ( Beheshtirouy, S; Gharekhani, A; Khoshbaten, M; Rezaee, H; Shayanrad, S, 2023) |
| "Treatment with pioglitazone or nicorandil either alone or in combination successfully ameliorated the deleterious effects of HFD on the all previous parameters." | 5.42 | Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. ( Elshazly, SM, 2015) |
| "Rats treated with boswellic acids (125 or 250 mg/kg) or pioglitazone showed improved insulin sensitivity and a reduction in liver index, activities of liver enzymes, serum TNF-α and IL-6 as well as hepatic iNOS expression and HNE formation compared to HFD group." | 5.42 | Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. ( Abdelaziz, EZ; Barakat, BM; Bilasy, SE; Farag, NE; Fawzy, MS; Zaitone, SA, 2015) |
| "Pioglitazone is considered a potential therapy for non-alcoholic fatty liver disease (NAFLD)." | 5.41 | Response to pioglitazone in non-alcoholic fatty liver disease patients with ( Chen, H; Du, H; Jiang, Y; Li, M; Long, G; Ma, C; Ren, Y; Tian, J; Wang, Z; Xu, M; Xue, C; Zhao, Y, 2023) |
| " Referring to the lower surface under the cumulative ranking curves (SUCRA) and the league matrix table, exenatide and liraglutide, which are also glucagon-like peptide-1 receptor agonists (GLP-1RAs), showed excellent potential to reduce liver fat content, control glycemia, reduce body weight, and improve liver function and insulin resistance." | 5.41 | Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials. ( Ba, Y; Deng, M; Fan, H; Fan, Y; Lu, Q; Ren, L; Wang, H; Wang, Z; Wen, Y; Yan, J; Zhang, R, 2023) |
| " Dapagliflozin has shown non-inferiority compared with pioglitazone for glycemic control, and superiority regarding weight reduction in patients with type 2 diabetes." | 5.41 | Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. ( Aoki, S; Atsumi, T; Cho, KY; Kameda, H; Kurihara, Y; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Takase, T; Taneda, S; Yamamoto, K, 2021) |
| "Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease, NCT00633282 ." | 5.41 | Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. ( Chang, X; Gao, J; Ma, S; Wang, L; Wu, W; Xia, M; Yan, H, 2021) |
| "One-year treatment with pioglitazone even at low dosage significantly improved liver steatosis and inflammation, systemic and adipose tissue insulin resistance in patients with T2D." | 5.41 | Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. ( Bozzetto, L; Carli, F; Della Pepa, G; Gastaldelli, A; Masulli, M; Riccardi, G; Rivellese, AA; Russo, M; Vaccaro, O; Vetrani, C; Vitale, M, 2021) |
| "Biochemical markers of NAFLD worsened over time." | 5.40 | Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014) |
| " pioglitazone on hepatic fat content and serum fetuin A levels in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease." | 5.34 | Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. ( Qu, XN; Sun, ZY; Zhang, LY; Zhang, Y, 2020) |
| "Treatment of patients with prediabetes or T2DM with pioglitazone for up to 3 years was associated with decreased BMD at the level of the lumbar spine." | 5.30 | Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. ( Barb, D; Bril, F; Bruder, JM; Cusi, K; Lomonaco, R; Orsak, B; Portillo-Sanchez, P, 2019) |
| "The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone." | 5.22 | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. ( Bril, F; Cusi, K; Darland, C; Hardies, J; Hecht, J; Lomonaco, R; Musi, N; Orsak, B; Ortiz-Lopez, C; Portillo-Sanchez, P; Tio, F; Webb, A, 2016) |
| " Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3." | 5.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
| "To systematically evaluate the effects of pioglitazone in the treatment of patients with prediabetes or T2DM combined with NAFLD." | 5.12 | Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. ( Fu, J; Lian, J, 2021) |
| "We performed a meta-analysis of epidemiological studies evaluating exposure to pioglitazone and the risk for bladder cancer and compared these results to the drug's effects on cardiovascular disease (CVD) and non-alcoholic steatohepatitis (NASH)." | 4.98 | An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. ( Davidson, MB; Pan, D, 2018) |
| " Reversal of lipotoxicity with pioglitazone is associated with significant histological improvement, which occurs within 6 months and persists with continued treatment (or for at least 3 years) in patients with prediabetes or type 2 diabetes, holding potential to modify the natural history of the disease." | 4.93 | Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. ( Cusi, K, 2016) |
| " Current treatment strategies aim to improve insulin resistance via weight loss and exercise, improve insulin sensitivity by the use of insulin-sensitizing agents (for example, pioglitazone) and reduce oxidative stress by the use of antioxidants, such as vitamin E." | 4.87 | Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. ( Adams, LA; Smith, BW, 2011) |
| "5 % cholic acid and 60 % cocoa butter for 6 weeks causing a number of metabolic and hepatic alterations including insulin resistance, dyslipidemia, systemic inflammation, increased hepatic oxidative stress and lipid peroxidation, hepatic steatosis, lobular inflammation, as well as increased markers of liver inflammation and hepatocyte apoptosis." | 4.12 | Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. ( Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A, 2022) |
| "The aim: To study the association between the effectiveness of treatment with pioglitazone non-alcoholic fatty liver disease (NAFLD) in patients with obesity and PPARG rs1801282 (Pro12Ala)-polymorphism in Ukrainians." | 4.02 | ASSOCIATION ANALYSIS OF PIOGLITAZONE EFFECTIVENESS IN TREATMENT OF NAFLD PATIENTS WITH OBESITY AND PPARG RS1801282 (PRO12ALA) GENOTYPE. ( Koliada, AK; Martynchuk, OA; Melnyk, NH; Rudenko, NN; Shypulin, VP; Tishchenko, VV, 2021) |
| " Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs)." | 3.91 | Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. ( Chaiyakunapruk, N; Chongmelaxme, B; Dilokthornsakul, P; Phisalprapa, P; Sawangjit, R, 2019) |
| " However, liraglutide induced weight loss, improved glycaemic control, reduced ALT and AST and showed some beneficial effects upon steatosis and lobular inflammation." | 3.91 | Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. ( Brockbank, S; Bruun, MF; Cruwys, S; Daniels, SJ; Detlefsen, S; Hein, P; Henriksen, K; Hjuler, ST; Karsdal, MA; Leeming, DJ, 2019) |
| "Pioglitazone is effective in improving insulin resistance and liver histology in patients with nonalcoholic steatohepatitis (NASH)." | 3.88 | Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. ( Abdo, K; Andrews, P; Bril, F; Cusi, K; Frye, RF; Garrett, TJ; Guingab, J; Jose, D; Kalavalapalli, S; Koelmel, JP; Li, WY; Sunny, NE; Yost, RA, 2018) |
| "The study showed pioglitazone might exert an inhibitory effect on hepatic inflammation and fibrosis in NAFLD." | 3.85 | Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. ( Deng, W; Meng, Z; Sun, A; Yang, Z, 2017) |
| "To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone." | 3.83 | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016) |
| "This quasi experimental study was carried out to compare the efficacy of Pentoxifylline versus Pioglitazone in non-alcoholic fatty liver disease (NAFLD) among newly detected glucose intolerant patients attended at GHPD, BIRDEM, Dhaka, Bangladesh from March 2011 to May 2012." | 3.83 | Comparative Study between Pentoxifylline and Pioglitazone in the Treatment of Non-Alcoholic Fatty Liver Disease among Newly Detected Glucose Intolerant Patients. ( Ahmed, H; Alam, MS; Chowdhury, M; Karim, MR; Paul, RK; Saha, A, 2016) |
| " Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients." | 3.78 | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ( Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H, 2012) |
| "Pioglitazone (Pio) is an approved diabetes medicine with proven efficacy in non-alcoholic steatohepatitis (NASH); PXL065 is a novel related oral agent which has been shown to retain Pio's efficacy in preclinical NASH models, with reduced potential for PPARγ-driven side effects." | 3.30 | Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1). ( Bedossa, P; Bolze, S; Cusi, K; Dewitt, S; Dubourg, J; Fouqueray, P; Grouin, JM; Hallakou-Bozec, S; Harrison, SA; Moller, DE; Ratziu, V; Thang, C, 2023) |
| "Combined treatment with pioglitazone-metformin can effectively reduce liver fat content and gamma-GT level in newly diagnosed diabetic patients with nonalcoholic fatty liver disease, and adverse events do not increase compared with the control group, showing good safety and tolerance." | 3.30 | Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study. ( Jianfang, F; Jianrong, L; Jie, M; Jing, X; Jingxuan, L; Kaiyan, M; Mengying, L; Qian, X; Qingzhen, H; Qiuhe, J; Taixiong, C; Wanxia, X; Wenjuan, Y; Xiling, G, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is a complex metabolic disorder that increases the risk for cardiovascular disease in patients with type 2 diabetes mellitus (T2DM)." | 3.30 | Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial. ( Ajdarkosh, H; Attaran, F; Emami, S; Ismail-Beigi, F; Khamseh, ME; Khoonsari, M; Malek, M; Sohrabi, M, 2023) |
| "The incidence of nonalcoholic fatty liver disease (NAFLD) has recently increased and is related to obesity and the associated surge in type 2 diabetes mellitus (T2DM) and metabolic syndromes." | 3.11 | Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. ( Honda, Y; Imajo, K; Kessoku, T; Kirikoshi, H; Kobayashi, T; Nakajima, A; Nogami, A; Ogawa, Y; Saito, S; Taguri, M; Yoneda, M, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing." | 3.01 | Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials. ( An, J; Sohn, JH, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD), sarcopenia and sarcopenic obesity (SO) are highly prevalent conditions that may coexist, especially in the aging population, without any approved pharmacologic treatment for all of them." | 3.01 | Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease. ( Mantzoros, CS; Polyzos, SA; Vachliotis, ID, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) is often observed in individuals with type 2 diabetes mellitus, and it is known that the presence of type 2 diabetes mellitus leads to the aggravation of NAFLD." | 2.94 | Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. ( Fushimi, Y; Hirata, Y; Hirukawa, H; Irie, S; Kaku, K; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakamura, Y; Nakanishi, S; Nakashima, K; Nishioka, M; Obata, A; Sanada, J; Shimoda, M; Tanabe, A; Tatsumi, F, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and is becoming the most frequent indication of liver transplantation." | 2.90 | Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. ( Anushiravani, A; Haddadi, N; Mohammadkarimi, V; Pourfarmanbar, M, 2019) |
| "While vitamin E has shown to improve nonalcoholic steatohepatitis (NASH) in patients without diabetes, information on patients with type 2 diabetes mellitus (T2DM) is lacking." | 2.90 | Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. ( Biernacki, DM; Bril, F; Cusi, K; Hecht, J; Kalavalapalli, S; Lai, J; Lomonaco, R; Orsak, BK; Subbarayan, SK; Suman, A; Tio, F, 2019) |
| "Statin therapy is safe in patients with prediabetes/T2DM and NASH." | 2.84 | Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. ( Bril, F; Cusi, K; Hecht, J; Lomonaco, R; Orsak, B; Portillo Sanchez, P; Tio, F, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is known to be a health-related problem; there is no proven treatment for NAFLD." | 2.84 | Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. ( Akbarieh, S; Gohari, S; Heydari, AH; Jafari, S; Jameshoorani, M; Sajedi, B; Yaghoubi, M, 2017) |
| "Heart failure (HF) and nonalcoholic fatty liver disease (NAFLD) are 2 conditions that have become important global public health problems." | 2.82 | Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. ( Benfari, G; Bonapace, S; Byrne, CD; Mantovani, A; Simon, TG; Targher, G, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease." | 2.82 | Non-alcoholic fatty liver disease and type 2 diabetes mellitus. II. Treatment ( Pár, A; Pár, G; Wittmann, I, 2022) |
| "Pioglitazone intake is effective in nonalcoholic steatohepatitis management." | 2.82 | Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs. ( Bu, H; Takahashi, H; Wang, H; Zhao, W; Zhao, Y, 2022) |
| "Non-alcoholic steatohepatitis (NASH) is a common cause of serum alanine aminotransferase (ALT) elevations and chronic liver disease, but it is unclear how well ALT elevations reflect the liver injury." | 2.78 | Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. ( Clark, JM; Hoofnagle, JH; Kleiner, DE; Kowdley, KV; Loomba, R; Neuschwander-Tetri, BA; Sanyal, AJ; Tonascia, J; Van Natta, ML, 2013) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and has an estimated global prevalence of 25%." | 2.72 | Non-alcoholic fatty liver disease: Current therapeutic options. ( Majumdar, A; Tsochatzis, EA; Verbeek, J, 2021) |
| "However, most patients with NAFLD/NASH will die from a vascular cause." | 2.72 | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. ( Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A, 2021) |
| "Twenty-six studies (n=946 NAFLD patients) were included." | 2.72 | Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. ( Kumar, J; Kumar, S; Memon, RS; Menezes, RG; Rizwan, T; Shahid, I; Siddiqi, TJ; Usman, MS; Zaman, M, 2021) |
| "Pioglitazone was also the best therapy for steatosis and lobular inflammation reduction." | 2.72 | Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. ( Bornstein, SR; Capristo, E; De Gaetano, A; Labbate, L; Maltese, S; Mingrone, G; Panunzi, S; Pompili, M; Verrastro, O, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) exists as a spectrum ranging from simple steatosis to histologically defined hepatocyte injury and inflammatory changes that define steatohepatitis (NASH), and increase risk for fibrosis." | 2.72 | Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes. ( Pajvani, UB; Salomao, MA; Steinman, JB, 2021) |
| "Pioglitazone has been shown to consistently induce resolution of NASH in both patients with or without diabetes in a total of 498 participants in five randomized controlled trials (RCTs), but with modest effects on liver fibrosis." | 2.66 | A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. ( Cusi, K, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is associated with various metabolic diseases, including type 2 diabetes mellitus." | 2.66 | Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. ( Kim, KS; Lee, BW, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is an often unrecognized complication of type 2 diabetes (T2DM) associated with significant economic burden and poor long-term hepatic and extrahepatic outcomes." | 2.66 | Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. ( Budd, J; Cusi, K, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western societies and a major cause of hepatic disease worldwide." | 2.61 | Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! ( Mikhailidis, DP; Ranjbar, G; Sahebkar, A, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) affects one-third of the population worldwide, of which a substantial number of patients suffer from non-alcoholic steatohepatitis (NASH)." | 2.61 | Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. ( Boeckmans, J; Buyl, K; De Kock, J; M Rodrigues, R; Natale, A; Rogiers, V; Rombaut, M; Vanhaecke, T, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD) is an increasingly dominant cause of liver disease worldwide." | 2.61 | Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. ( Cheung, A; Figueredo, C; Rinella, ME, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD), the most prevalent cause of chronic liver disease worldwide, is strongly associated with obesity and insulin resistance." | 2.61 | Nonalcoholic Fatty Liver Disease and Obesity Treatment. ( Brunner, KT; Henneberg, CJ; Long, MT; Wilechansky, RM, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western industrialised countries." | 2.61 | Diagnosis and management of non-alcoholic fatty liver disease. ( Byrne, CD; Jennison, E; Patel, J; Scorletti, E, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is a major national and international health burden." | 2.61 | Position statement on the diagnosis and management of non-alcoholic fatty liver disease. ( Al-Hamoudi, WK; Al-Judaibi, B; Al-Osaimi, A; Alswat, KA; Alturaify, N; Elsiesy, HA; Fallatah, HI; Qutub, AN, 2019) |
| "Metformin has been largely studied in the past years without convincing evidence of improving NAFLD." | 2.58 | The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). ( Iogna Prat, L; Tsochatzis, EA, 2018) |
| "Standard treatment of obesity with lifestyle interventions including diet, exercise, and behavioral modification has been shown to improve NASH as well as reduce cardiovascular dysfunction." | 2.58 | Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. ( Kumar, RB; Mathews, SE; Shukla, AP, 2018) |
| "Pharmacotherapy used to treat type 2 diabetes mellitus (T2DM) is facing a paradigm shift in clinical practice with recent cardiovascular (CV) outcome trials having a substantial impact on drug prescription with treatment having a more tailored approach." | 2.58 | Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. ( De Ponti, F; Marchesini, G; Mazzotti, A; Poluzzi, E; Raschi, E, 2018) |
| "It also provides an overview of NAFLD agents currently under development." | 2.55 | Current and future pharmacologic treatment of nonalcoholic steatohepatitis. ( Banini, BA; Sanyal, AJ, 2017) |
| " The suggestion of this Expert Panel is that, pending forthcoming randomized clinical trials, physicians should consider using a PPARgamma agonist, such as pioglitazone, or, statin use in those with NAFLD/NASH at high CVD or HCC risk, alone and/or preferably in combination with each other or with ezetimibe, for the primary or secondary prevention of CVD, and the avoidance of cirrhosis, liver transplantation or HCC, bearing in mind that CVD is the main cause of death in NAFLD/NASH patients." | 2.55 | The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. ( Alexandrides, TK; Athyros, VG; Bilianou, H; Cholongitas, E; Doumas, M; Elisaf, MS; Ganotakis, ES; Germanidis, G; Giouleme, O; Goudevenos, J; Karagiannis, A; Karvounis, C; Katsiki, N; Kotsis, V; Kountouras, J; Liberopoulos, E; Mantzoros, C; Mikhailidis, DP; Pitsavos, C; Polyzos, S; Rallidis, LS; Richter, D; Tsapas, AG; Tselepis, AD; Tsioufis, K; Tziomalos, K; Tzotzas, T; Vasiliadis, TG; Vlachopoulos, C, 2017) |
| "Pharmacotherapy for nonalcoholic fatty liver disease (NAFLD) has not yet been approved by the US Food and Drug Administration." | 2.55 | Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. ( Mao, YM; Tang, JT, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is prevalent in patients with obesity or type 2 diabetes." | 2.55 | Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. ( Bril, F; Cusi, K; Sunny, NE, 2017) |
| "NASH, the more aggressive form of NAFLD, may progress to cirrhosis and hepatocellular carcinoma." | 2.55 | Therapies in non-alcoholic steatohepatitis (NASH). ( Oseini, AM; Sanyal, AJ, 2017) |
| "Type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD) are highly prevalent in the community, and share common pathogenic mechanisms." | 2.55 | Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? ( Caletti, MT; Forlani, G; Marchesini, G; Marchignoli, F; Mazzotti, A, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in the USA with a growing prevalence worldwide." | 2.53 | Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. ( Corey, KE; Rinella, ME, 2016) |
| "Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in the western world because of its close association with obesity, insulin resistance and dyslipidaemia." | 2.52 | Nonalcoholic fatty liver disease: new treatments. ( Anstee, QM; Day, CP; Hardy, T, 2015) |
| "In patients with nonalcoholic steatohepatitis, half of deaths are due to cardiovascular disease and malignancy, yet awareness of this remains low." | 2.52 | Nonalcoholic fatty liver disease: a systematic review. ( Rinella, ME, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal serum aminotransferase levels in both developed and developing countries." | 2.52 | Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. ( Ahmed, A; Harrison, SA; Wong, RJ, 2015) |
| "Nonalcoholic fatty liver disease is the most common cause of chronic liver disease in Western countries, and consists of a spectrum of histopathological changes that range in severity from simple steatosis to steatohepatitis to cirrhosis." | 2.50 | State of the art: treatment of nonalcoholic steatohepatitis. ( Loomba, R; Pearlman, M, 2014) |
| "Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined." | 2.50 | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver dysfunction worldwide." | 2.49 | Current concepts and management approaches in nonalcoholic fatty liver disease. ( Attar, BM; Van Thiel, DH, 2013) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide." | 2.49 | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. ( Belfiore, A; Fruci, B; Giuliano, S; Malaguarnera, R; Mazza, A, 2013) |
| "Nonalcoholic fatty liver disease (NAFLD) is considered the most common liver disorder in the Western world." | 2.49 | Nonalcoholic fatty liver disease: current issues and novel treatment approaches. ( Bril, F; Cusi, K; Lomonaco, R; Sunny, NE, 2013) |
| "When pioglitazone (n = 137) was analysed alone, the improvement in fibrosis with pioglitazone (n = 137) vs." | 2.48 | Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. ( Boettcher, E; Csako, G; Loomba, R; Pucino, F; Wesley, R, 2012) |
| "The prevalence of NAFLD is likely to increase over time due to the epidemics of obesity and diabetes." | 2.48 | Vitamin E and nonalcoholic fatty liver disease. ( Pacana, T; Sanyal, AJ, 2012) |
| "Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world." | 2.47 | Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. ( Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N, 2011) |
| "At EOS, subjects with type 2 diabetes treated with triple therapy had less hepatic steatosis and fibrosis versus conventional therapy; the severity of hepatic steatosis and fibrosis were both strongly and inversely correlated with insulin resistance; and changes in liver fibrosis scores (APRI, NFS, Fibrosis-4, and AST/ALT ratio) have limited value in predicting response to therapy." | 1.72 | Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). ( Abdelgani, S; Abdul-Ghani, M; Adams, J; Alatrach, M; Alkhouri, N; Cersosimo, E; Clarke, GD; DeFronzo, RA; Gastaldelli, A; Lavynenko, O; Li, J; Puckett, C; Triplitt, C; Vasquez, JA, 2022) |
| "After NAFLD induction, the serum level of IL-10 significantly increased and serum IL-1β, TNF-α levels significantly decreased by injection of both doses of Shilajit and pioglitazone (P<0." | 1.72 | Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease. ( Asadikaram, G; Ghezelbash, B; Khaksari, M; Shahrokhi, M; Shahrokhi, N; Shirazpour, S, 2022) |
| "Associations between HRQoL and NAFLD disease activity score in the secondary analysis were of similar magnitude." | 1.72 | Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life. ( Aveyard, P; Cobbold, JF; Heath, L; Koutoukidis, DA; Tomlinson, JW, 2022) |
| "The HFHFr diet induced severe NAFLD in terms of steatosis, hepatitis, and fibrosis." | 1.72 | The effects of the voglibose on non-alcoholic fatty liver disease in mice model. ( Bae, J; Cha, BS; Kang, ES; Lee, BW; Lee, JY; Lee, M; Lee, YH; Shin, E, 2022) |
| "37 patients with NAFLD in summer 2019 were enrolled in this study." | 1.72 | Improvement of thiol groups and total antioxidant capacity in patients with non-alcoholic fatty liver after treatment with pioglitazone. ( Hooshyar, R; Salmani, F; Tajik, H; Tavakoli, T; Zarban, A, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) was evaluated by abdominal ultrasound, and fibrosis stages were evaluated at baseline and 8 months." | 1.72 | The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. ( Fu, BY; Wang, XJ, 2022) |
| "Screening for NAFLD remains challenging especially in those with diabetes because liver enzymes are often in the normal range and the performance of NAFLD scores is limited." | 1.62 | Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity? ( Kahl, S; Roden, M; Schröder, B, 2021) |
| "In patient with NAFLD, interpretation of LSM in association with CAP scores may provide helpful information sparing unnecessary liver biopsy." | 1.51 | Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. ( Lee, HW; Lee, JI; Lee, KS, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) has become a major cause of chronic liver disease." | 1.51 | Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. ( Chen, L; Gao, YS; Li, YH; Sun, Y; Wang, M; Wang, Y; Wu, MY; Yang, JM; Zhang, SJ; Zhang, XL; Zheng, FJ; Zhou, L; Zhou, YM, 2019) |
| "Pioglitazone has been used for the treatment of nonalcoholic fatty liver disease (NAFLD) related to diabetes." | 1.51 | Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet. ( de Mendonça, M; de Sousa, É; Dos Santos, BAC; Rodrigues, AC, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common clinico-pathological conditions that affect millions of patients worldwide." | 1.48 | Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. ( Bhoi, B; Das, N; Giri, SR; Jain, MR; Kadam, S; Karmakar, E; Patel, H; Patel, PR; Ranvir, R; Rath, A; Rathod, R; Roy, SS; Swain, P; Trivedi, C; Wahli, W, 2018) |
| "Pioglitazone was associated with a significantly greater insulin sensitivity in adipose tissue of patients with diabetes vs without diabetes (P < ." | 1.48 | Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. ( Bril, F; Clark, VC; Cusi, K; Kalavalapalli, S; Liu, IC; Lomonaco, R; Orsak, B; Soldevila-Pico, C; Tio, F, 2018) |
| "TGJ may be a therapy for the NAFLD with T2DM rats by modulating the inflammatory response and the oxidative stress capacity." | 1.48 | Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus. ( Fan, Y; He, Z; Hu, A; Li, J; Xiong, W; Yin, Q; Zhang, J; Zhou, G, 2018) |
| "Pioglitazone is a safe and effective option to manage patients with type 2 diabetes and nonalcoholic steatohepatitis (NASH)." | 1.46 | Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. ( Bril, F; Cusi, K; Frye, RF; Kalavalapalli, S; Kawaguchi-Suzuki, M, 2017) |
| "Treatment with pioglitazone caused an increase in body weight gain in Pemt(-/-) mice that was mainly due to increased adiposity." | 1.43 | Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice. ( Armstrong, EA; Gao, X; Jacobs, RL; Kassiri, Z; Lehner, R; Lingrell, S; Quiroga, AD; Takawale, A; van der Veen, JN; Vance, DE; Yager, JY, 2016) |
| "Treatment with pioglitazone or nicorandil either alone or in combination successfully ameliorated the deleterious effects of HFD on the all previous parameters." | 1.42 | Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. ( Elshazly, SM, 2015) |
| "Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting renal glucose reabsorption and thereby causes a subsequent antihyperglycemic effect." | 1.42 | Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. ( Hayashizaki-Someya, Y; Koide, K; Kurosaki, E; Mitori, H; Takakura, S; Takasu, T; Yamazaki, S, 2015) |
| "Rats treated with boswellic acids (125 or 250 mg/kg) or pioglitazone showed improved insulin sensitivity and a reduction in liver index, activities of liver enzymes, serum TNF-α and IL-6 as well as hepatic iNOS expression and HNE formation compared to HFD group." | 1.42 | Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. ( Abdelaziz, EZ; Barakat, BM; Bilasy, SE; Farag, NE; Fawzy, MS; Zaitone, SA, 2015) |
| "Non-alcoholic fatty liver disease (NAFLD) defines a wide spectrum of liver diseases that extends from simple steatosis to non-alcoholic steatohepatitis." | 1.42 | LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). ( Costa Oliveira, A; de Lima, Mdo C; de Oliveira Cipriano Torres, D; dos Santos Gomes, FO; dos Santos Silva, B; dos Santos, LA; Lima Ribeiro, E; Peixoto, CA; Pitta, Ida R; Soares e Silva, AK, 2015) |
| "Biochemical markers of NAFLD worsened over time." | 1.40 | Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014) |
| "Nonalcoholic steatohepatitis (NASH) is the commonest liver disease in developed countries." | 1.38 | Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. ( Craig, JC; George, J; Mahady, SE; Wong, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 107 (66.05) | 24.3611 |
| 2020's | 55 (33.95) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, J | 1 |
| Rotter, M | 1 |
| Weiser, T | 1 |
| Wittmann, S | 1 |
| Weizel, L | 1 |
| Kaiser, A | 1 |
| Heering, J | 1 |
| Goebel, T | 1 |
| Angioni, C | 1 |
| Wurglics, M | 1 |
| Paulke, A | 1 |
| Geisslinger, G | 1 |
| Kahnt, A | 1 |
| Steinhilber, D | 1 |
| Proschak, E | 1 |
| Merk, D | 1 |
| Romero, FA | 1 |
| Jones, CT | 1 |
| Xu, Y | 2 |
| Fenaux, M | 1 |
| Halcomb, RL | 1 |
| Shypulin, VP | 1 |
| Martynchuk, OA | 1 |
| Rudenko, NN | 1 |
| Koliada, AK | 1 |
| Tishchenko, VV | 1 |
| Melnyk, NH | 1 |
| Majumdar, A | 1 |
| Verbeek, J | 1 |
| Tsochatzis, EA | 2 |
| Colca, JR | 1 |
| Scherer, PE | 1 |
| Lavynenko, O | 1 |
| Abdul-Ghani, M | 1 |
| Alatrach, M | 1 |
| Puckett, C | 1 |
| Adams, J | 1 |
| Abdelgani, S | 1 |
| Alkhouri, N | 1 |
| Triplitt, C | 1 |
| Clarke, GD | 1 |
| Vasquez, JA | 1 |
| Li, J | 3 |
| Cersosimo, E | 1 |
| Gastaldelli, A | 2 |
| DeFronzo, RA | 1 |
| Mantovani, A | 1 |
| Byrne, CD | 2 |
| Benfari, G | 1 |
| Bonapace, S | 1 |
| Simon, TG | 1 |
| Targher, G | 1 |
| Lule, KO | 1 |
| Akarsu, E | 1 |
| Sayiner, ZA | 1 |
| Lule, NO | 1 |
| Balci, SO | 1 |
| Demirel, C | 1 |
| Bozdag, Z | 1 |
| Korkmaz, M | 1 |
| Yilmaz, I | 1 |
| Xie, W | 1 |
| Liu, P | 1 |
| Gao, F | 1 |
| Gu, Y | 2 |
| Xiao, Y | 1 |
| Wu, P | 1 |
| Chen, B | 2 |
| Liu, W | 1 |
| Liu, Q | 1 |
| Ghezelbash, B | 1 |
| Shahrokhi, N | 1 |
| Khaksari, M | 1 |
| Asadikaram, G | 1 |
| Shahrokhi, M | 1 |
| Shirazpour, S | 1 |
| Yoneda, M | 5 |
| Kobayashi, T | 3 |
| Honda, Y | 3 |
| Ogawa, Y | 4 |
| Kessoku, T | 3 |
| Imajo, K | 3 |
| Nogami, A | 2 |
| Taguri, M | 2 |
| Kirikoshi, H | 2 |
| Saito, S | 3 |
| Nakajima, A | 4 |
| Pár, A | 1 |
| Wittmann, I | 1 |
| Pár, G | 1 |
| Heath, L | 1 |
| Aveyard, P | 1 |
| Tomlinson, JW | 1 |
| Cobbold, JF | 1 |
| Koutoukidis, DA | 1 |
| Bae, J | 1 |
| Lee, JY | 1 |
| Shin, E | 1 |
| Lee, M | 1 |
| Lee, YH | 1 |
| Lee, BW | 2 |
| Kang, ES | 1 |
| Cha, BS | 1 |
| Shaaban, HH | 1 |
| Alzaim, I | 1 |
| El-Mallah, A | 1 |
| Aly, RG | 1 |
| El-Yazbi, AF | 1 |
| Wahid, A | 1 |
| Zhao, Y | 7 |
| Zhao, W | 3 |
| Wang, H | 4 |
| Bu, H | 3 |
| Takahashi, H | 3 |
| Bril, F | 14 |
| Kalavalapalli, S | 6 |
| Lomonaco, R | 9 |
| Cusi, K | 20 |
| Sanyal, AJ | 11 |
| Williams, SA | 2 |
| Lavine, JE | 2 |
| Neuschwander-Tetri, BA | 5 |
| Alexander, L | 2 |
| Ostroff, R | 2 |
| Biegel, H | 2 |
| Kowdley, KV | 4 |
| Chalasani, N | 5 |
| Dasarathy, S | 2 |
| Diehl, AM | 3 |
| Loomba, R | 7 |
| Hameed, B | 2 |
| Behling, C | 2 |
| Kleiner, DE | 5 |
| Karpen, SJ | 2 |
| Williams, J | 2 |
| Jia, Y | 2 |
| Yates, KP | 3 |
| Tonascia, J | 3 |
| An, J | 1 |
| Sohn, JH | 1 |
| Camacho, RC | 1 |
| Polidori, D | 1 |
| Chen, T | 1 |
| Hsu, HH | 1 |
| Gao, B | 1 |
| Marella, M | 1 |
| Lubomirski, M | 1 |
| Beavers, T | 1 |
| Cabrera, J | 1 |
| Wong, P | 1 |
| Nawrocki, AR | 1 |
| Sun, L | 1 |
| He, Y | 1 |
| Yang, L | 1 |
| Deng, C | 1 |
| Zhou, R | 1 |
| Kong, T | 1 |
| Zhang, W | 3 |
| Chen, Y | 1 |
| Shi, J | 1 |
| Khoshbaten, M | 1 |
| Beheshtirouy, S | 1 |
| Shayanrad, S | 1 |
| Gharekhani, A | 1 |
| Rezaee, H | 1 |
| Harrison, SA | 3 |
| Thang, C | 1 |
| Bolze, S | 1 |
| Dewitt, S | 1 |
| Hallakou-Bozec, S | 1 |
| Dubourg, J | 1 |
| Bedossa, P | 1 |
| Ratziu, V | 1 |
| Grouin, JM | 1 |
| Moller, DE | 1 |
| Fouqueray, P | 1 |
| Wang, Z | 2 |
| Du, H | 1 |
| Ren, Y | 1 |
| Ma, C | 1 |
| Chen, H | 1 |
| Li, M | 1 |
| Tian, J | 1 |
| Xue, C | 1 |
| Long, G | 1 |
| Xu, M | 1 |
| Jiang, Y | 1 |
| Jianfang, F | 1 |
| Wanxia, X | 1 |
| Xiling, G | 1 |
| Jing, X | 1 |
| Wenjuan, Y | 1 |
| Jianrong, L | 1 |
| Qingzhen, H | 1 |
| Kaiyan, M | 1 |
| Jingxuan, L | 1 |
| Taixiong, C | 1 |
| Qian, X | 1 |
| Mengying, L | 1 |
| Jie, M | 1 |
| Qiuhe, J | 1 |
| Polyzos, SA | 2 |
| Vachliotis, ID | 1 |
| Mantzoros, CS | 3 |
| Liu, J | 2 |
| Wang, D | 1 |
| Xie, Z | 1 |
| Ding, L | 1 |
| Li, S | 1 |
| Ma, X | 1 |
| Ren, J | 1 |
| Xiao, C | 1 |
| Yang, C | 1 |
| Xiao, X | 2 |
| Attaran, F | 1 |
| Emami, S | 1 |
| Sohrabi, M | 1 |
| Malek, M | 1 |
| Ajdarkosh, H | 1 |
| Khoonsari, M | 1 |
| Ismail-Beigi, F | 1 |
| Khamseh, ME | 1 |
| Kasahara, N | 1 |
| Imi, Y | 1 |
| Amano, R | 1 |
| Shinohara, M | 1 |
| Okada, K | 1 |
| Hosokawa, Y | 1 |
| Imamori, M | 1 |
| Tomimoto, C | 1 |
| Kunisawa, J | 1 |
| Kishino, S | 1 |
| Ogawa, J | 1 |
| Ogawa, W | 1 |
| Hosooka, T | 1 |
| Deng, M | 1 |
| Wen, Y | 1 |
| Yan, J | 1 |
| Fan, Y | 2 |
| Zhang, R | 1 |
| Ren, L | 1 |
| Ba, Y | 1 |
| Lu, Q | 1 |
| Fan, H | 1 |
| Lee, JI | 1 |
| Lee, HW | 1 |
| Lee, KS | 1 |
| Yang, JM | 1 |
| Sun, Y | 1 |
| Wang, M | 1 |
| Zhang, XL | 1 |
| Zhang, SJ | 1 |
| Gao, YS | 1 |
| Chen, L | 1 |
| Wu, MY | 1 |
| Zhou, L | 1 |
| Zhou, YM | 1 |
| Wang, Y | 1 |
| Zheng, FJ | 1 |
| Li, YH | 1 |
| Barb, D | 2 |
| Lai, J | 2 |
| Ranjbar, G | 1 |
| Mikhailidis, DP | 3 |
| Sahebkar, A | 2 |
| Tahara, A | 2 |
| Takasu, T | 2 |
| Blazina, I | 1 |
| Selph, S | 1 |
| Boeckmans, J | 1 |
| Natale, A | 1 |
| Rombaut, M | 1 |
| Buyl, K | 1 |
| Rogiers, V | 1 |
| De Kock, J | 1 |
| Vanhaecke, T | 1 |
| M Rodrigues, R | 1 |
| Zhang, LY | 1 |
| Qu, XN | 1 |
| Sun, ZY | 1 |
| Zhang, Y | 1 |
| Sumida, Y | 1 |
| Okanoue, T | 1 |
| Kinoshita, T | 1 |
| Shimoda, M | 1 |
| Nakashima, K | 1 |
| Fushimi, Y | 1 |
| Hirata, Y | 1 |
| Tanabe, A | 1 |
| Tatsumi, F | 1 |
| Hirukawa, H | 1 |
| Sanada, J | 1 |
| Kohara, K | 1 |
| Irie, S | 1 |
| Kimura, T | 1 |
| Nakamura, Y | 1 |
| Nishioka, M | 1 |
| Obata, A | 1 |
| Nakanishi, S | 1 |
| Mune, T | 1 |
| Kaku, K | 1 |
| Kaneto, H | 1 |
| Gurka, MJ | 1 |
| Mack, JA | 1 |
| Chi, X | 1 |
| DeBoer, MD | 1 |
| Tavakoli, T | 1 |
| Zarban, A | 1 |
| Hooshyar, R | 1 |
| Salmani, F | 1 |
| Tajik, H | 1 |
| Connelly, MA | 1 |
| Velez Rivera, J | 1 |
| Guyton, JR | 1 |
| Siddiqui, MS | 1 |
| Mahjoubin-Tehran, M | 1 |
| De Vincentis, A | 1 |
| Atkin, SL | 1 |
| Jamialahmadi, T | 1 |
| Kim, KS | 1 |
| Kumar, J | 1 |
| Memon, RS | 1 |
| Shahid, I | 1 |
| Rizwan, T | 1 |
| Zaman, M | 1 |
| Menezes, RG | 1 |
| Kumar, S | 1 |
| Siddiqi, TJ | 1 |
| Usman, MS | 1 |
| Budd, J | 1 |
| Mohammed, ED | 1 |
| Zhang, Z | 1 |
| Tian, W | 1 |
| Gangarapu, V | 1 |
| Al-Gendy, AA | 1 |
| Chen, J | 1 |
| Wei, J | 1 |
| Sun, B | 1 |
| Cho, KY | 1 |
| Nakamura, A | 1 |
| Omori, K | 1 |
| Takase, T | 1 |
| Miya, A | 1 |
| Yamamoto, K | 2 |
| Nomoto, H | 1 |
| Kameda, H | 1 |
| Taneda, S | 1 |
| Kurihara, Y | 1 |
| Aoki, S | 1 |
| Atsumi, T | 1 |
| Miyoshi, H | 1 |
| Panunzi, S | 1 |
| Maltese, S | 1 |
| Verrastro, O | 1 |
| Labbate, L | 1 |
| De Gaetano, A | 1 |
| Pompili, M | 1 |
| Capristo, E | 1 |
| Bornstein, SR | 1 |
| Mingrone, G | 1 |
| Shen, B | 1 |
| Lu, LG | 1 |
| Yan, H | 1 |
| Wu, W | 1 |
| Chang, X | 1 |
| Xia, M | 1 |
| Ma, S | 1 |
| Wang, L | 2 |
| Gao, J | 1 |
| Ozaki, A | 1 |
| Yamanaka, T | 1 |
| Iwasaki, T | 1 |
| Kurihashi, T | 1 |
| Lian, J | 2 |
| Fu, J | 2 |
| Fu, BY | 1 |
| Wang, XJ | 1 |
| Schröder, B | 1 |
| Kahl, S | 1 |
| Roden, M | 1 |
| Della Pepa, G | 1 |
| Russo, M | 1 |
| Vitale, M | 1 |
| Carli, F | 1 |
| Vetrani, C | 1 |
| Masulli, M | 1 |
| Riccardi, G | 1 |
| Vaccaro, O | 1 |
| Rivellese, AA | 1 |
| Bozzetto, L | 1 |
| Steinman, JB | 1 |
| Salomao, MA | 1 |
| Pajvani, UB | 1 |
| Majzoub, AM | 1 |
| Nayfeh, T | 1 |
| Barnard, A | 1 |
| Munaganuru, N | 1 |
| Dave, S | 1 |
| Singh, S | 2 |
| Murad, MH | 2 |
| Banini, BA | 2 |
| Rotman, Y | 1 |
| Kawaguchi-Suzuki, M | 2 |
| Frye, RF | 3 |
| Athyros, VG | 2 |
| Alexandrides, TK | 1 |
| Bilianou, H | 1 |
| Cholongitas, E | 1 |
| Doumas, M | 2 |
| Ganotakis, ES | 1 |
| Goudevenos, J | 1 |
| Elisaf, MS | 1 |
| Germanidis, G | 1 |
| Giouleme, O | 1 |
| Karagiannis, A | 1 |
| Karvounis, C | 1 |
| Katsiki, N | 1 |
| Kotsis, V | 1 |
| Kountouras, J | 2 |
| Liberopoulos, E | 1 |
| Pitsavos, C | 1 |
| Polyzos, S | 1 |
| Rallidis, LS | 1 |
| Richter, D | 1 |
| Tsapas, AG | 1 |
| Tselepis, AD | 1 |
| Tsioufis, K | 1 |
| Tziomalos, K | 1 |
| Tzotzas, T | 1 |
| Vasiliadis, TG | 1 |
| Vlachopoulos, C | 1 |
| Mantzoros, C | 1 |
| Portillo Sanchez, P | 1 |
| Orsak, B | 4 |
| Hecht, J | 3 |
| Tio, F | 4 |
| Han, L | 1 |
| Shen, WJ | 1 |
| Bittner, S | 1 |
| Kraemer, FB | 1 |
| Azhar, S | 1 |
| Townsend, SA | 1 |
| Newsome, PN | 1 |
| Regamey, F | 1 |
| Srinivas, NR | 1 |
| Ito, D | 1 |
| Shimizu, S | 1 |
| Inoue, K | 1 |
| Saito, D | 1 |
| Yanagisawa, M | 1 |
| Inukai, K | 1 |
| Akiyama, Y | 1 |
| Morimoto, Y | 1 |
| Noda, M | 1 |
| Shimada, A | 1 |
| Hsiao, PJ | 1 |
| Chiou, HC | 1 |
| Jiang, HJ | 1 |
| Lee, MY | 1 |
| Hsieh, TJ | 1 |
| Kuo, KK | 1 |
| Deng, W | 1 |
| Meng, Z | 1 |
| Sun, A | 1 |
| Yang, Z | 1 |
| Yaghoubi, M | 1 |
| Jafari, S | 1 |
| Sajedi, B | 1 |
| Gohari, S | 1 |
| Akbarieh, S | 1 |
| Heydari, AH | 1 |
| Jameshoorani, M | 1 |
| Tang, JT | 1 |
| Mao, YM | 1 |
| Davidson, MB | 1 |
| Pan, D | 1 |
| Jain, MR | 1 |
| Giri, SR | 1 |
| Bhoi, B | 1 |
| Trivedi, C | 1 |
| Rath, A | 1 |
| Rathod, R | 1 |
| Ranvir, R | 1 |
| Kadam, S | 1 |
| Patel, H | 1 |
| Swain, P | 1 |
| Roy, SS | 1 |
| Das, N | 1 |
| Karmakar, E | 1 |
| Wahli, W | 1 |
| Patel, PR | 1 |
| Clark, VC | 1 |
| Soldevila-Pico, C | 1 |
| Liu, IC | 1 |
| Amano, Y | 1 |
| Tsuchiya, S | 1 |
| Imai, M | 1 |
| Tohyama, K | 1 |
| Matsukawa, J | 1 |
| Isono, O | 1 |
| Yasuno, H | 1 |
| Enya, K | 1 |
| Koumura, E | 1 |
| Nagabukuro, H | 1 |
| Koelmel, JP | 1 |
| Abdo, K | 1 |
| Guingab, J | 1 |
| Andrews, P | 1 |
| Li, WY | 1 |
| Jose, D | 1 |
| Yost, RA | 1 |
| Garrett, TJ | 1 |
| Sunny, NE | 3 |
| Toriniwa, Y | 1 |
| Saito, T | 1 |
| Miyajima, K | 1 |
| Ishii, Y | 1 |
| Uno, K | 1 |
| Maekawa, T | 1 |
| Matsui, T | 1 |
| Kume, S | 1 |
| Yamada, T | 1 |
| Ohta, T | 1 |
| Ullman, K | 1 |
| Iogna Prat, L | 1 |
| Heebøll, S | 1 |
| Vilstrup, H | 1 |
| Grønbæk, H | 1 |
| Portillo-Sanchez, P | 2 |
| Bruder, JM | 1 |
| Mathews, SE | 1 |
| Kumar, RB | 1 |
| Shukla, AP | 1 |
| Raschi, E | 1 |
| Mazzotti, A | 2 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Marchesini, G | 2 |
| Chongmelaxme, B | 1 |
| Phisalprapa, P | 1 |
| Sawangjit, R | 1 |
| Dilokthornsakul, P | 1 |
| Chaiyakunapruk, N | 1 |
| Xiong, W | 1 |
| Hu, A | 1 |
| He, Z | 1 |
| Zhang, J | 1 |
| Zhou, G | 1 |
| Yin, Q | 1 |
| Brunt, EM | 2 |
| Wilson, LA | 4 |
| Cheung, A | 1 |
| Figueredo, C | 1 |
| Rinella, ME | 3 |
| Daniels, SJ | 1 |
| Leeming, DJ | 1 |
| Detlefsen, S | 1 |
| Bruun, MF | 1 |
| Hjuler, ST | 1 |
| Henriksen, K | 1 |
| Hein, P | 1 |
| Karsdal, MA | 1 |
| Brockbank, S | 1 |
| Cruwys, S | 1 |
| Corey, KE | 3 |
| Altinbas, A | 1 |
| Chung, RT | 1 |
| Krauss, RM | 1 |
| Anushiravani, A | 1 |
| Haddadi, N | 1 |
| Pourfarmanbar, M | 1 |
| Mohammadkarimi, V | 1 |
| Brunner, KT | 1 |
| Henneberg, CJ | 1 |
| Wilechansky, RM | 1 |
| Long, MT | 1 |
| Jennison, E | 1 |
| Patel, J | 1 |
| Scorletti, E | 1 |
| Povsic, M | 1 |
| Oliver, L | 1 |
| Jiandani, NR | 1 |
| Perry, R | 1 |
| Bottomley, J | 1 |
| de Mendonça, M | 1 |
| Dos Santos, BAC | 1 |
| de Sousa, É | 1 |
| Rodrigues, AC | 1 |
| Alswat, KA | 1 |
| Fallatah, HI | 1 |
| Al-Judaibi, B | 1 |
| Elsiesy, HA | 1 |
| Al-Hamoudi, WK | 1 |
| Qutub, AN | 1 |
| Alturaify, N | 1 |
| Al-Osaimi, A | 1 |
| Biernacki, DM | 1 |
| Subbarayan, SK | 1 |
| Suman, A | 1 |
| Orsak, BK | 1 |
| Attar, BM | 1 |
| Van Thiel, DH | 1 |
| Hoofnagle, JH | 1 |
| Van Natta, ML | 1 |
| Clark, JM | 1 |
| Takei, Y | 1 |
| Riche, DM | 1 |
| Fleming, JW | 1 |
| Malinowski, SS | 1 |
| Black, CA | 1 |
| Miller, KH | 1 |
| Wofford, MR | 1 |
| Fruci, B | 1 |
| Giuliano, S | 1 |
| Mazza, A | 1 |
| Malaguarnera, R | 1 |
| Belfiore, A | 1 |
| Xu, YZ | 1 |
| Liu, B | 2 |
| Wu, R | 2 |
| Yang, YY | 1 |
| Xiao, XQ | 1 |
| Zhang, X | 2 |
| Surapaneni, KM | 3 |
| Jainu, M | 1 |
| Pearlman, M | 1 |
| Åberg, F | 1 |
| Koljonen, V | 1 |
| Nikkilä, K | 1 |
| Boyd, S | 1 |
| Arola, J | 1 |
| Isoniemi, H | 1 |
| Sanchez, PP | 1 |
| Priya, VV | 1 |
| Mallika, J | 2 |
| Herrigel, DJ | 1 |
| Moss, RA | 1 |
| Vuppalanchi, R | 1 |
| Cummings, OW | 1 |
| Elshazly, SM | 1 |
| Hayashizaki-Someya, Y | 1 |
| Kurosaki, E | 1 |
| Mitori, H | 1 |
| Yamazaki, S | 1 |
| Koide, K | 1 |
| Takakura, S | 1 |
| Zaitone, SA | 1 |
| Barakat, BM | 1 |
| Bilasy, SE | 1 |
| Fawzy, MS | 1 |
| Abdelaziz, EZ | 1 |
| Farag, NE | 1 |
| Hardy, T | 1 |
| Anstee, QM | 1 |
| Day, CP | 1 |
| Soares e Silva, AK | 1 |
| de Oliveira Cipriano Torres, D | 1 |
| dos Santos Gomes, FO | 1 |
| dos Santos Silva, B | 1 |
| Lima Ribeiro, E | 1 |
| Costa Oliveira, A | 1 |
| dos Santos, LA | 1 |
| de Lima, Mdo C | 1 |
| Pitta, Ida R | 1 |
| Peixoto, CA | 1 |
| Khera, R | 1 |
| Allen, AM | 1 |
| Ahmed, A | 1 |
| Wong, RJ | 1 |
| Vishnu Priya, V | 1 |
| van der Veen, JN | 1 |
| Lingrell, S | 1 |
| Gao, X | 1 |
| Quiroga, AD | 1 |
| Takawale, A | 1 |
| Armstrong, EA | 1 |
| Yager, JY | 1 |
| Kassiri, Z | 1 |
| Lehner, R | 1 |
| Vance, DE | 1 |
| Jacobs, RL | 1 |
| Abd El-Haleim, EA | 1 |
| Bahgat, AK | 1 |
| Saleh, S | 1 |
| García Díaz, E | 1 |
| Guagnozzi, D | 1 |
| Gutiérrez, V | 1 |
| Mendoza, C | 1 |
| Maza, C | 1 |
| Larrañaga, Y | 1 |
| Perdomo, D | 1 |
| Godoy, T | 1 |
| Taleb, G | 1 |
| Karim, MR | 1 |
| Ahmed, H | 1 |
| Paul, RK | 1 |
| Chowdhury, M | 1 |
| Alam, MS | 1 |
| Saha, A | 1 |
| Ortiz-Lopez, C | 1 |
| Hardies, J | 1 |
| Darland, C | 1 |
| Musi, N | 1 |
| Webb, A | 1 |
| Vilar-Gomez, E | 1 |
| Adams, LA | 2 |
| Bugianesi, E | 1 |
| Perazzo, H | 1 |
| Dufour, JF | 1 |
| Musso, G | 2 |
| Cassader, M | 2 |
| Paschetta, E | 2 |
| Gambino, R | 2 |
| Oseini, AM | 1 |
| Caletti, MT | 1 |
| Marchignoli, F | 1 |
| Forlani, G | 1 |
| Sutton, SK | 1 |
| Thomas, JA | 1 |
| Gupta, R | 1 |
| Aithal, GP | 1 |
| Yabiku, K | 1 |
| Mutoh, A | 1 |
| Miyagi, K | 1 |
| Takasu, N | 1 |
| Yee, HF | 1 |
| Schenker, S | 1 |
| Zaitone, S | 1 |
| Hassan, N | 1 |
| El-Orabi, N | 1 |
| El-Awady, el-S | 1 |
| Smith, BW | 1 |
| Samson, SL | 1 |
| Sathyanarayana, P | 1 |
| Jogi, M | 1 |
| Gonzalez, EV | 1 |
| Gutierrez, A | 1 |
| Krishnamurthy, R | 1 |
| Muthupillai, R | 1 |
| Chan, L | 1 |
| Bajaj, M | 1 |
| Boettcher, E | 1 |
| Csako, G | 1 |
| Pucino, F | 1 |
| Wesley, R | 1 |
| Shyangdan, D | 1 |
| Clar, C | 1 |
| Ghouri, N | 1 |
| Henderson, R | 1 |
| Gurung, T | 1 |
| Preiss, D | 1 |
| Sattar, N | 1 |
| Fraser, A | 1 |
| Waugh, N | 1 |
| Kawai, D | 1 |
| Takaki, A | 1 |
| Nakatsuka, A | 1 |
| Wada, J | 1 |
| Tamaki, N | 1 |
| Yasunaka, T | 1 |
| Koike, K | 2 |
| Tsuzaki, R | 1 |
| Matsumoto, K | 1 |
| Miyake, Y | 1 |
| Shiraha, H | 1 |
| Morita, M | 1 |
| Makino, H | 1 |
| Bell, LN | 1 |
| Wang, J | 1 |
| Muralidharan, S | 1 |
| Chalasani, S | 1 |
| Fullenkamp, AM | 1 |
| McCullough, AJ | 1 |
| Bass, NM | 1 |
| Unalp-Arida, A | 1 |
| Mahady, SE | 1 |
| Wong, G | 1 |
| Craig, JC | 1 |
| George, J | 1 |
| Ohki, T | 1 |
| Isogawa, A | 1 |
| Iwamoto, M | 1 |
| Ohsugi, M | 1 |
| Yoshida, H | 1 |
| Toda, N | 1 |
| Tagawa, K | 1 |
| Omata, M | 1 |
| Pacana, T | 1 |
| Zhang, F | 1 |
| Yang, Y | 1 |
| Zhou, H | 1 |
| Wan, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus[NCT00633282] | Phase 2 | 184 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158] | Phase 3 | 56 participants (Anticipated) | Interventional | 2022-11-30 | Not yet recruiting | ||
| Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM).[NCT00994682] | Phase 4 | 176 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Calisthenics Versus High-intensity Interval Exercises on Health-related Outcomes in Patients With Non-alcoholic Fatty Liver[NCT06032650] | 60 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | |||
| NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment[NCT01002547] | Phase 4 | 105 participants (Actual) | Interventional | 2010-06-24 | Completed | ||
| Effect of Low-Dose Pioglitazone in Patients With Nonalcoholic Steatohepatitis (NASH)[NCT04501406] | Phase 2 | 166 participants (Anticipated) | Interventional | 2020-12-15 | Recruiting | ||
| Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)[NCT00063622] | Phase 3 | 247 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| The Role of Microbiome Reprogramming on Liver Fat Accumulation[NCT03914495] | 57 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to PI carefully considered multiple factors and decided to close study to any further enrollment.) | |||
| Metabolic Surgery for the Treatment and Understanding of Non-Alcoholic Steato-Hepatitis (NASH): Weight-Dependent and Weight-Independent Effects[NCT04282005] | 28 participants (Anticipated) | Interventional | 2020-02-13 | Recruiting | |||
| Predictors of Improvement of Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients Undergoing Bariatric Surgery[NCT04059029] | 200 participants (Anticipated) | Observational | 2016-10-31 | Enrolling by invitation | |||
| Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet[NCT03141008] | 54 participants (Actual) | Observational | 2017-09-15 | Completed | |||
| Non Invasive Evaluation of Liver Fibrosis and Steatosis in Type 2 Diabetic Patient in Assiut University Hospitals[NCT05605717] | 60 participants (Anticipated) | Observational | 2022-11-01 | Not yet recruiting | |||
| Quantitative Detection Efficiency of Ultrasound Derived Fat Fraction (UDFF) as a Non-invasive Alternative for Nonalcoholic Fatty Liver Disease (CHESS2303): a Multicenter Prospective Study[NCT05802199] | 300 participants (Anticipated) | Observational [Patient Registry] | 2023-01-01 | Recruiting | |||
| Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease[NCT03459079] | Phase 2 | 54 participants (Anticipated) | Interventional | 2018-08-14 | Recruiting | ||
| Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus[NCT01432405] | Phase 4 | 24 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Suppression of free fatty acids by low dose insulin (i.e., percentage of reduction of plasma FFA with low dose insulin infusion compared to the baseline state). This was calculated as: 100*((plasma FFA without insulin - plasma FFA with insulin infusion)/plasma FFA without insulin). All measurements are obtained at the same time point during an euglycemic insulin clamp. (NCT00994682)
Timeframe: 18 months
| Intervention | % of suppression of FFA (Mean) |
|---|---|
| Placebo | 46.1 |
| Pioglitazone | 65.9 |
Suppression of endogenous glucose production (Supp EGP) by low dose insulin (i.e., percentage of reduction of EGP with low dose insulin infusion compared to the baseline state). This was calculated as: 100*((EGP without insulin - EGP with insulin infusion)/EGP without insulin). All measurements are obtained at the same time point during an euglycemic insulin clamp. (NCT00994682)
Timeframe: 18 months
| Intervention | % of suppression of EGP (Mean) |
|---|---|
| Placebo | 37.7 |
| Pioglitazone | 55.3 |
Liver fat content was calculated as the fat fraction: 100*(area under the curve [AUC] of fat peak / [AUC of fat peak + AUC of water peak]). (NCT00994682)
Timeframe: 18 months
| Intervention | percentage of fat in liver (Mean) |
|---|---|
| Placebo | 11 |
| Pioglitazone | 7 |
"Number of patients with reduction of at least 2 points in the nonalcoholic fatty liver disease activity score (NAS) (with reduction in at least 2 different histological categories) without worsening of fibrosis. NAS is the sum of the separate scores for steatosis (0-3), hepatocellular ballooning (0-2) and lobular inflammation (0-3), and ranges from 0-8 .~The scoring system is based on the following grading:~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT00994682)
Timeframe: At 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Pioglitazone | 29 |
Resolution of NASH was defined as absence of NASH after 18 months of therapy in patients with definite NASH (presence of zone 3 accentuation of macrovesicular steatosis of any grade, hepatocellular ballooning of any degree, and lobular inflammatory infiltrates of any amount) at baseline. (NCT00994682)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 10 |
| Pioglitazone | 26 |
Number of patients with osteoporotic fractures (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pioglitazone | 0 |
| Placebo | 0 |
Rate of glucose disappearance (Rd) during high-dose insulin infusion. The rate of plasma glucose disappearance was calculated using Steele's non-steady-state equation. (NCT00994682)
Timeframe: 18 months
| Intervention | mg/kgLBM/min (Mean) |
|---|---|
| Placebo | 5.4 |
| Pioglitazone | 9.6 |
Total body fat measured by dual-energy x-ray absorptiometry (DXA) (NCT00994682)
Timeframe: Months 18
| Intervention | Percentage of body weight that is fat (Mean) |
|---|---|
| Placebo | 36 |
| Pioglitazone | 36 |
(NCT00994682)
Timeframe: Months 18 and 36
| Intervention | kg/m^2 (Mean) | |
|---|---|---|
| BMI Month 18 | BMI Month 36 | |
| Pioglitazone | 34.6 | 35.2 |
| Placebo | 34.6 | 36.7 |
Bone mineral density measured at the levels of spine, femoral neck, hip, and wrist by DXA. (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | g/cm^2 (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Spine BMD at month 18 | Femoral Neck BMD at month 18 | Hip BMD at month 18 | Wrist BMD at month 18 | Spine BMD at month 36 | Femoral Neck BMD at month 36 | Hip BMD at month 36 | Wrist BMD at month 36 | |
| Pioglitazone | 1.04 | 0.84 | 1.05 | 0.76 | 1.06 | 0.84 | 1.02 | 0.75 |
| Placebo | 1.10 | 0.86 | 1.05 | 0.78 | 1.10 | 0.84 | 1.06 | 0.77 |
Homeostatic model assessment of insulin resistance (HOMA-IR) is a method for assessing insulin resistance (IR) from basal fasting plasma glucose (FPG) and fasting plasma insulin (FPI). It is calculated as (FPG x FPI)/405. (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | Arbitrary units (Mean) | |
|---|---|---|
| HOMA-IR month 18 | HOMA-IR month 36 | |
| Pioglitazone | 1.4 | 1.6 |
| Placebo | 4.3 | 2.3 |
"Number of patients with improvement of at least 1 grade in each of the histological parameters.~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal, 1A = Mild, zone 3, perisinusoidal delicate fibrosis; 1B = Moderate, zone 3, perisinusoidal dense fibrosis; 1C = Portal/periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis" (NCT00994682)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | 35 | 25 | 25 | 20 |
| Placebo | 13 | 11 | 12 | 13 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | U/L (Mean) | |||
|---|---|---|---|---|
| ALT at month 18 | AST at month 18 | ALT at month 36 | AST at month 36 | |
| Pioglitazone | 27 | 29 | 27 | 27 |
| Placebo | 44 | 38 | 32 | 30 |
Mean change in individual scores compared to baseline. Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis (NCT00994682)
Timeframe: Baseline and Month 18
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | -1.1 | -0.6 | -0.6 | -0.5 |
| Placebo | -0.2 | -0.1 | -0.2 | 0 |
Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis (NCT00994682)
Timeframe: Month 36
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | 0.97 | 0.81 | 0.22 | 0.66 |
| Placebo | 1.56 | 1.30 | 0.33 | 0.89 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | μg/ml (Mean) | |
|---|---|---|
| Adiponectin month 18 | Adiponectin month 36 | |
| Pioglitazone | 22.8 | 24.2 |
| Placebo | 9.1 | 24.0 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | U/L (Mean) | |
|---|---|---|
| CK-18 month 18 | CK-18 month 36 | |
| Pioglitazone | 186 | 151 |
| Placebo | 314 | 245 |
Number of patients developing T2DM and number of patients regressing to NGT among patients with prediabetes (IFG/IGT). (NCT00994682)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Patients developing T2DM | Patients regressing to NGT | |
| Pioglitazone | 1 | 10 |
| Placebo | 2 | 1 |
Weight (in kg) / (Height [in m] x Height [in m]) (NCT01002547)
Timeframe: Month 18
| Intervention | kg/m2 (Mean) |
|---|---|
| Placebo | -0.6 |
| Vitamin E | 0.1 |
| Pioglitazone + Vitamin E | 1.4 |
Change from baseline after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | 6 |
| Vitamin E | -3 |
| Pioglitazone + Vitamin E | -16 |
Change from baseline after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | uU/ml (Mean) |
|---|---|
| Placebo | 3 |
| Vitamin E | -3 |
| Pioglitazone + Vitamin E | -3 |
Change from baseline in plasma HDL-cholesterol after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -1 |
| Vitamin E | 1 |
| Pioglitazone + Vitamin E | 3 |
Change from baseline in plasma LDL-cholesterol after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -12 |
| Vitamin E | 0 |
| Pioglitazone + Vitamin E | -4 |
Change from baseline in intrahepatic triglyceride content after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | percentage (Mean) |
|---|---|
| Placebo | 1 |
| Vitamin E | -6 |
| Pioglitazone + Vitamin E | -10 |
"Number of patients with reduction of at least 2 points in the nonalcoholic fatty liver disease activity score (NAS) (with reduction in at least 2 different histological categories) without worsening of fibrosis. NAS is the sum of the separate scores for steatosis (0-3), hepatocellular ballooning (0-2) and lobular inflammation (0-3), and ranges from 0-8 .~The scoring system is based on the following grading:~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT01002547)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 7 |
| Vitamin E | 13 |
| Pioglitazone + Vitamin E | 24 |
This is a method for assessing insulin resistance (IR) based on measurements of glucose and insulin during the oral glucose tolerance test. The formula used is = (10000/(SQRT(fasting plasma glucose * fasting plasma insulin * ((fasting plasma glucose * 15 + glucose at minute 30 * 30 + glucose at minute 60 * 30 + glucose at minute 90 * 30 + glucose at minute 120 * 15)/120)*((fasting plasma insulin * 15 + insulin at minute 30 * 30 + insulin at minute 60 * 30 + insulin at minute 90 * 30 + insulin at minute 120 * 15)/120))), with a lower value representing worse insulin resistance. (NCT01002547)
Timeframe: Month 18
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 2.53 |
| Vitamin E | 2.31 |
| Pioglitazone + Vitamin E | 4.02 |
Resolution of NASH was defined as absence of NASH after 18 months of therapy in patients with definite NASH (presence of zone 3 accentuation of macrovesicular steatosis of any grade, hepatocellular ballooning of any degree, and lobular inflammatory infiltrates of any amount) at baseline. (NCT01002547)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| Vitamin E | 14 |
| Pioglitazone + Vitamin E | 20 |
Change from baseline in plasma ALT after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | U/L (Mean) |
|---|---|
| Placebo | -6 |
| Vitamin E | -24 |
| Pioglitazone + Vitamin E | -18 |
Change from baseline in plasma AST after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | U/L (Mean) |
|---|---|
| Placebo | -8 |
| Vitamin E | -15 |
| Pioglitazone + Vitamin E | -10 |
Change from baseline in total body fat by DEX after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | percentage (Mean) |
|---|---|
| Placebo | 0 |
| Vitamin E | 0 |
| Pioglitazone + Vitamin E | 2 |
Change from baseline in plasma total cholesterol after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -11 |
| Vitamin E | 5 |
| Pioglitazone + Vitamin E | 1 |
Change from baseline in plasma triglycerides after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | mg/dl (Median) |
|---|---|
| Placebo | 13 |
| Vitamin E | 14 |
| Pioglitazone + Vitamin E | -2 |
Change from baseline in weight (NCT01002547)
Timeframe: Month 18
| Intervention | kg (Mean) |
|---|---|
| Placebo | -0.8 |
| Vitamin E | 0.5 |
| Pioglitazone + Vitamin E | 5.7 |
"Number of patients with improvement of at least 1 grade in each of the histological parameters.~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x.~Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning.~Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT01002547)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone + Vitamin E | 32 | 25 | 23 | 19 |
| Placebo | 15 | 14 | 11 | 10 |
| Vitamin E | 24 | 13 | 18 | 19 |
"Mean change in individual scores compared to baseline. Steatosis range 0-3, where: 0 = <5% fat; 1 = 5-33% fat; 2 = >33-66% fat; 3 = >66% fat.~Lobular Inflammation, range 0-3, where: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x.~Hepatocyte Ballooning, range 0-2, where: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning.~Fibrosis stage, range 0-4, where: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT01002547)
Timeframe: Month 18
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone + Vitamin E | -1.3 | -0.6 | -0.6 | -0.6 |
| Placebo | -0.4 | -0.2 | -0.1 | -0.3 |
| Vitamin E | -1.0 | -0.4 | -0.5 | -0.6 |
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score, which indicates improvement in fibrosis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 31 |
| Vitamin E | 33 |
| Placebo | 22 |
Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning. This secondary outcome measure is the number of participants that experienced a decrease in hepatocellular ballooning score, which indicates improvement in hepatocellular ballooning. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 31 |
| Vitamin E | 40 |
| Placebo | 21 |
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score, which indicates improvement in lobular inflammation. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 41 |
| Vitamin E | 43 |
| Placebo | 25 |
Total nonalcoholic fatty liver disease (NAFLD) activity was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a scale of 0 to 2). The primary outcome was an improvement in histological findings from baseline to 96 weeks, which required an improvement by 1 or more points in the hepatocellular ballooning score; no increase in the fibrosis score; and either a decrease in the activity score for nonalcoholic fatty liver disease to a score of 3 or less or a decrease in the activity score of at least 2 points, with at least a 1-point decrease in either the lobular inflammation or steatosis score. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 27 |
| Vitamin E | 36 |
| Placebo | 16 |
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score, which indicates improvement in steatosis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 48 |
| Vitamin E | 43 |
| Placebo | 22 |
The criteria for nonalcoholic steatohepatitis was definite or possible steatohepatitis (assessed by a pathologist) with an activity score of 5 or more, or definite steatohepatitis (confirmed by two pathologists) with an activity score of 4. This secondary outcome measure is the number of participants who met this definition at baseline and did not meet this definition after 96 weeks of treatment and thus had a resolution of steatohepatitis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 33 |
| Vitamin E | 29 |
| Placebo | 15 |
The effect of exenatide and pioglitazone on liver fat content after one year of treatment in patients with type 2 diabetes. (NCT01432405)
Timeframe: one year
| Intervention | percent of liver fat (Mean) |
|---|---|
| Pioglitazone and Exenatide | 4.7 |
| Pioglitazone | 6.5 |
the effect of the intervention on plasma adiponectin levels. (NCT01432405)
Timeframe: one year
| Intervention | microgram per ml (Mean) |
|---|---|
| Pioglitazone and Exenatide | 23.2 |
| Pioglitazone | 15.8 |
64 reviews available for pioglitazone and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Age | 2020 |
Non-alcoholic fatty liver disease: Current therapeutic options.
Topics: Exercise; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone | 2021 |
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.
Topics: Adipose Tissue; Chronic Disease; COVID-19; Diabetes Mellitus, Type 2; Humans; Inflammation; Insulin; | 2022 |
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week.
Topics: Bariatric Surgery; Dysbiosis; Glucagon-Like Peptide-1 Receptor; Heart Failure; Humans; Hypoglycemic | 2022 |
Non-alcoholic fatty liver disease and type 2 diabetes mellitus. II. Treatment
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitaz | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials.
Topics: Fibrosis; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized C | 2023 |
Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled tria
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypogl | 2023 |
Response to pioglitazone in non-alcoholic fatty liver disease patients with
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lipids; Non-alcoholic Fatty Liver Disease; P | 2023 |
Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.
Topics: Aged; Diet; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Sarcopenia | 2023 |
Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Insulin Resistance | 2023 |
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Glucagon-Like Peptide 1; | 2019 |
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Topics: Blood Glucose; Body Weight; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide | 2019 |
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Topics: Chalcones; Diabetes Mellitus, Type 2; Drug Development; Fatty Liver; Humans; Hypoglycemic Agents; In | 2019 |
A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Non-alcoholic Fat | 2020 |
Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
Topics: Chenodeoxycholic Acid; Clinical Trials as Topic; Fibroblast Growth Factors; Glucagon-Like Peptides; | 2020 |
Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Development; Humans; Hydroxymethylglutaryl-CoA Reduct | 2020 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Di | 2021 |
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease.
Topics: Diabetes Mellitus, Type 2; Humans; Non-alcoholic Fatty Liver Disease; Pharmaceutical Preparations; P | 2020 |
Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver; Non-alcoholic Fatty Liver Disease; Ob | 2021 |
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Non-alcoholic Fatty Live | 2020 |
Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis.
Topics: Adult; Bariatric Surgery; Bayes Theorem; Female; Humans; Liver; Male; Network Meta-Analysis; Non-alc | 2021 |
Efficacy and safety of drugs for nonalcoholic steatohepatitis.
Topics: Diabetes Mellitus, Type 2; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pharmaceutica | 2021 |
Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Bayes Theorem; Blood Glucose; Body Mass Index; Bo | 2021 |
Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitaz | 2021 |
Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes.
Topics: Hepatocytes; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone | 2021 |
Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.
Topics: Biopsy; Humans; Liver Cirrhosis; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Pioglitaz | 2021 |
Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
Topics: Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Liver Neopl | 2017 |
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Topics: Animals; Cardiovascular Diseases; Drug Therapy, Combination; Fatty Liver; Humans; Hydroxymethylgluta | 2017 |
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Non-alcoholic Fatty | 2017 |
Review article: new treatments in non-alcoholic fatty liver disease.
Topics: Drug Design; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; MAP Kinase Kinase Kinase 5; Non-a | 2017 |
Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
Topics: Antioxidants; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyp | 2017 |
An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis.
Topics: Cardiovascular Diseases; Cohort Studies; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Dise | 2018 |
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone | 2018 |
[Treatment of non-alcoholic fatty liver disease].
Topics: Bariatric Surgery; Chalcones; Chenodeoxycholic Acid; Critical Pathways; Humans; Hypoglycemic Agents; | 2018 |
Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Diet; Exercise; Heart Diseases; Humans; Life Style; Non-al | 2018 |
Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Non-al | 2018 |
Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.
Topics: Adult; Diet; Disease Progression; Drug Development; Humans; Life Style; Non-alcoholic Fatty Liver Di | 2019 |
Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients.
Topics: Biomarkers; Biopsy; Diagnostic Imaging; Diet; Disease Progression; Humans; Hypoglycemic Agents; Life | 2019 |
Nonalcoholic Fatty Liver Disease and Obesity Treatment.
Topics: Bariatric Surgery; Body Weight; Diet; Exercise; Glucagon-Like Peptide 1; Humans; Inflammation; Insul | 2019 |
Diagnosis and management of non-alcoholic fatty liver disease.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Disease Management; Elasticity Imaging Techniques; Exercise | 2019 |
A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH).
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Guidelines as Topic; Humans | 2019 |
Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Chalcones; Chenodeoxycholic Acid; Diagnostic Imaging; Healthy | 2019 |
Current concepts and management approaches in nonalcoholic fatty liver disease.
Topics: Cognitive Behavioral Therapy; Diet Therapy; Exercise Therapy; Fatty Liver; Humans; Hypoglycemic Agen | 2013 |
Treatment of non-alcoholic fatty liver disease.
Topics: Animals; Fatty Liver; Humans; Inflammation; Insulin Resistance; Life Style; Liver Transplantation; M | 2013 |
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Re | 2013 |
State of the art: treatment of nonalcoholic steatohepatitis.
Topics: Antioxidants; Exercise; Humans; Hypoglycemic Agents; Life Style; Non-alcoholic Fatty Liver Disease; | 2014 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp | 2014 |
Nonalcoholic fatty liver disease: new treatments.
Topics: Antioxidants; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistanc | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Topics: Chenodeoxycholic Acid; Drug Therapy, Combination; Humans; Non-alcoholic Fatty Liver Disease; Pioglit | 2015 |
Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
Topics: Bariatric Surgery; Diabetes Mellitus; Gastrointestinal Agents; Humans; Metabolic Syndrome; Non-alcoh | 2015 |
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Topics: Antioxidants; Bariatric Surgery; Exercise; Fatty Acids, Omega-6; Humans; Hydroxymethylglutaryl-CoA R | 2016 |
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; I | 2016 |
The therapeutic landscape of non-alcoholic steatohepatitis.
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Disease Progression; Humans; Hypoglycemic Agents; In | 2017 |
Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.
Topics: Animals; Fatty Liver; Glucagon-Like Peptide 1; Humans; Mitochondria; Non-alcoholic Fatty Liver Disea | 2017 |
Therapies in non-alcoholic steatohepatitis (NASH).
Topics: Carcinoma, Hepatocellular; Diet; Disease Progression; Exercise; Fibrosis; Humans; Hypoglycemic Agent | 2017 |
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-al | 2017 |
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liv | 2017 |
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.
Topics: Diabetes Mellitus, Type 2; Fatty Liver; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Diseas | 2011 |
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; | 2012 |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; | 2011 |
Vitamin E and nonalcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Diabetes Mellitus; Disease Models, Animal; Dose-Respons | 2012 |
Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Topics: Carcinoma, Hepatocellular; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Non-alcohol | 2013 |
26 trials available for pioglitazone and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Age | 2022 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Humans; Hypoglycemic Agents; Metformin; Non-alcoh | 2023 |
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Topics: Deuterium; Diabetes Mellitus; Double-Blind Method; Fibrosis; Humans; Liver; Non-alcoholic Fatty Live | 2023 |
Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study.
Topics: Diabetes Mellitus, Type 2; Humans; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Table | 2023 |
Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Iran; Non-alcoholic Fatty Liver Disease; | 2023 |
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Topics: Adult; Biomarkers; Biopsy; Female; Humans; Hypoglycemic Agents; Inflammation; Liver; Liver Cirrhosis | 2020 |
Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Adult; alpha-2-HS-Glycoprotein; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lira | 2020 |
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Fe | 2020 |
Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; gamma | 2021 |
Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism.
Topics: Berberine; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Male; Non-alcoholic Fatty Liver Disea | 2021 |
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Japan; Non-alcoholic Fatty Live | 2021 |
Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial.
Topics: Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglitazo | 2021 |
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Cardiovascular Diseases; Diabetes Mellitus, Type | 2017 |
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response R | 2017 |
Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Pressure; Body Mass Index; Diet; Exe | 2017 |
Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial.
Topics: Bone Density; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Non | 2019 |
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
Topics: Adult; Biomarkers; Biopsy; Dyslipidemias; E-Selectin; Female; Humans; Intercellular Adhesion Molecul | 2019 |
Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucos | 2019 |
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Biopsy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Hu | 2019 |
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Biopsy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Hu | 2019 |
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Biopsy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Hu | 2019 |
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Biopsy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Hu | 2019 |
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Antioxidants; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; M | 2013 |
NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Humans; Lipoproteins, H | 2015 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; | 2017 |
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, | 2011 |
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
Topics: Adipose Tissue; Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administratio | 2012 |
72 other studies available for pioglitazone and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents; Drug Discovery; Enzyme Inhibitors; Epoxide Hydrolases; HeLa Cells | 2017 |
ASSOCIATION ANALYSIS OF PIOGLITAZONE EFFECTIVENESS IN TREATMENT OF NAFLD PATIENTS WITH OBESITY AND PPARG RS1801282 (PRO12ALA) GENOTYPE.
Topics: Genetic Predisposition to Disease; Genotype; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Pio | 2021 |
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty | 2022 |
The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Insulin Receptor Sub | 2022 |
Platelet-neutrophil hybrid membrane-coated gelatin nanoparticles for enhanced targeting ability and intelligent release in the treatment of non-alcoholic steatohepatitis.
Topics: Animals; Gelatin; Liver; Nanoparticles; Neutrophils; Non-alcoholic Fatty Liver Disease; Pioglitazone | 2022 |
Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease.
Topics: Adiponectin; Animals; Cytokines; Diet, High-Fat; Glucose; Insulin Resistance; Interleukin-10; Liver; | 2022 |
Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.
Topics: Fibrosis; Humans; Ligands; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Patient Reported Outc | 2022 |
The effects of the voglibose on non-alcoholic fatty liver disease in mice model.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Fructose; Glucose; Glycoside Hydrolase Inhibitors; | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Chol | 2022 |
Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence.
Topics: Humans; Liver; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2023 |
Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence.
Topics: Humans; Liver; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2023 |
Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence.
Topics: Humans; Liver; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2023 |
Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence.
Topics: Humans; Liver; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2023 |
Validation of a diet-induced Macaca fascicularis model of non-alcoholic steatohepatitis with dietary and pioglitazone interventions.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Liver; Liver Cirrhosis; Macaca fascicularis; Non-al | 2023 |
Combination of Pioglitazone and Metformin Actions on Liver Lipid Metabolism in Obese Mice.
Topics: Animals; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Di | 2023 |
A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-β signaling in hepatic stellate cells.
Topics: Animals; Diet, High-Fat; Fibrosis; Gastrointestinal Microbiome; Hepatic Stellate Cells; Humans; Lino | 2023 |
Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
Topics: Adult; Biopsy; Disease Progression; Elasticity Imaging Techniques; Female; Follow-Up Studies; Humans | 2019 |
Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
Topics: Animals; Bupleurum; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Fructose; Humans; | 2019 |
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Progres | 2019 |
Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis.
Topics: Adult; Aspartate Aminotransferases; Biomarkers; Female; Humans; Male; Metabolic Syndrome; Middle Age | 2021 |
Improvement of thiol groups and total antioxidant capacity in patients with non-alcoholic fatty liver after treatment with pioglitazone.
Topics: Antioxidants; Humans; Lipid Peroxidation; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Piogl | 2022 |
Modulation of IR as a therapeutic target to prevent NASH using NRF from Diceratella elliptica (DC.) jonsell. Strong Nrf2 and leptin inducer as well as NF-kB inhibitor.
Topics: Animals; Brassicaceae; Diet, High-Fat; Glucosinolates; Insulin Resistance; Leptin; Liver; Male; NF-E | 2021 |
Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
Topics: Animals; Aquaporin 2; Body Fluids; Diabetes Mellitus, Type 2; Diuresis; Drinking; Glucosides; Hypogl | 2021 |
The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gliclazide; Humans; Hypoglycemic Agents; Liraglutide; Metformi | 2022 |
Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Non-alcoholic Fat | 2021 |
Treatment of NASH: What Helps Beyond Weight Loss?
Topics: Alcohol Drinking; Comorbidity; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Hum | 2017 |
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver; Non-alcoholic Fatty Liver Disease; Pi | 2018 |
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitaz | 2018 |
Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fibrosis; Humans; Hypoglycemic | 2017 |
Topics: Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled | 2016 |
Letter: clinical response to pioglitazone in nonalcoholic steatohepatitis [NASH] treatment-use of pharmacokinetic surrogate.
Topics: Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2017 |
Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis.
Topics: Animals; Autophagy; Cell Line; Diet, High-Fat; Disease Models, Animal; Humans; Insulin; Leupeptins; | 2017 |
Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study.
Topics: Animals; Biomarkers; Biopsy; Fibrosis; Gene Expression; Inflammation; Lipid Metabolism; Male; Mice; | 2017 |
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Diet, High-Fat; Fenofibrate; | 2018 |
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Biopsy; Diabetes Mellitus, Type 2; Female; Histocytochemistry; Humans; Hypo | 2018 |
Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.
Topics: Animals; Dose-Response Relationship, Drug; Drug Combinations; Hypoglycemic Agents; Liver; Liver Cirr | 2018 |
Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality.
Topics: Cardiovascular Diseases; Comorbidity; Epidemics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2018 |
Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.
Topics: Adipose Tissue; Amino Acids, Branched-Chain; Animals; Citric Acid Cycle; Diet; Female; Fructose; Hum | 2018 |
Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model.
Topics: Animals; Cholesterol; Diet; Disease Models, Animal; Eating; Female; Hypoglycemic Agents; Metformin; | 2018 |
THE HEPATITIS/DIABETES CONNECTION The Effect of Hep C cures on Type 2 diabetes still unknown.
Topics: Antiviral Agents; Comorbidity; Diabetes Mellitus, Type 2; Hepatitis B; Hepatitis B Vaccines; Hepatit | 2016 |
Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand.
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Hypoglycemic Agents; Liver Cirrhosis; Live | 2019 |
Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2018 |
Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Topics: Adult; Biopsy; Chenodeoxycholic Acid; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Mi | 2019 |
Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diet, High-F | 2019 |
Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet.
Topics: Adiponectin; Animals; Diet, High-Fat; Disease Models, Animal; Fibroblast Growth Factors; Gene Knocko | 2019 |
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug | 2014 |
Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis.
Topics: Adipose Tissue; Angiotensin-Converting Enzyme 2; Animals; Diet, High-Fat; Fatty Liver; Gene Expressi | 2014 |
Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis.
Topics: Animals; Antioxidants; Catalase; Citrates; Diet, High-Fat; Fatty Liver; Glutathione; Glutathione Per | 2014 |
Thiazolidinedione therapy versus lifestyle recommendation in the treatment of post-liver transplant graft steatosis.
Topics: Adult; Cohort Studies; Female; Finland; Humans; Hypoglycemic Agents; Life Style; Liver Transplantati | 2014 |
A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study.
Topics: Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Linear Models; Non-alcoholic Fatt | 2014 |
Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).
Topics: Animals; Antioxidants; Citric Acid; Cytochrome P-450 CYP2E1; Enzyme Inhibitors; Male; Non-alcoholic | 2014 |
Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Body Weight; | 2015 |
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
Topics: Amino Acids; Animals; Choline Deficiency; Food, Formulated; Glucosides; Hydroxyproline; Hypoglycemic | 2015 |
Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
Topics: Alanine Transaminase; Aldehydes; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Body We | 2015 |
LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
Topics: Animals; Cyclooxygenase 2; Diet, High-Fat; Disease Models, Animal; Epidermal Growth Factor; I-kappa | 2015 |
Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH).
Topics: Analysis of Variance; Animals; Antioxidants; Calcium Chelating Agents; Citric Acid; Disease Models, | 2015 |
Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.
Topics: Actins; Adipocytes, White; Adipose Tissue, White; Adiposity; Animals; Anti-Infective Agents; Cell Pr | 2016 |
Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; | 2016 |
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gl | 2016 |
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
Topics: Humans; Liraglutide; Liver; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk Factors; Thiazolid | 2016 |
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
Topics: Humans; Liraglutide; Liver; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk Factors; Thiazolid | 2016 |
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
Topics: Humans; Liraglutide; Liver; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk Factors; Thiazolid | 2016 |
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
Topics: Humans; Liraglutide; Liver; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk Factors; Thiazolid | 2016 |
Comparative Study between Pentoxifylline and Pioglitazone in the Treatment of Non-Alcoholic Fatty Liver Disease among Newly Detected Glucose Intolerant Patients.
Topics: Adult; Bangladesh; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Non- | 2016 |
Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis?
Topics: Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2016 |
Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitaz | 2016 |
Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists.
Topics: Animals; Biomedical Research; Humans; Hyperlipidemias; Hypoglycemic Agents; Ligands; Lipotropic Agen | 2017 |
Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges.
Topics: Fibrosis; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidine | 2017 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis.
Topics: Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2017 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis.
Topics: Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2017 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis.
Topics: Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2017 |
The Role of Pioglitazone in the Management of Nonalcoholic Steatohepatitis: Are We There Yet?
Topics: Humans; Hypoglycemic Agents; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiaz | 2017 |
Insulin sensitizers in nonalcoholic steatohepatitis.
Topics: Clinical Trials as Topic; Fatty Liver; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Non | 2011 |
Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Biomarkers; Body Weight; C | 2011 |
Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice.
Topics: Animals; Disease Progression; Fatty Liver; Hydrogen; Hypoglycemic Agents; Liver Neoplasms; Male; Mic | 2012 |
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis.
Topics: Combined Modality Therapy; Cost-Benefit Analysis; Fatty Liver; Humans; Hypoglycemic Agents; Life Sty | 2012 |
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Dru | 2012 |
Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
Topics: Animals; Body Weight; Cyclic AMP-Dependent Protein Kinases; Diet, High-Fat; Fatty Liver; Hypoglycemi | 2012 |